Publication

Peroxiredoxins in Cancer and Response to Radiation Therapies

Downloadable Content

Persistent URL
Last modified
  • 05/21/2025
Type of Material
Authors
    Tom E. Forshaw, Wake Forest School of MedicineReetta Holmila, Wake Forest School of MedicineKimberly J. Nelson, Wake Forest School of MedicineJoshua E. Lewis, Georgia Institute of TechnologyMelissa Kemp, Emory UniversityAllen W. Tsang, Wake Forest School of MedicineLeslie B. Poole, Wake Forest School of MedicineW. Todd Lowther, Wake Forest School of MedicineCristina M. Furdui, Wake Forest School of Medicine
Language
  • English
Date
  • 2019-01-01
Publisher
  • MDPI
Publication Version
Copyright Statement
  • © 2019 by the authors. Licensee MDPI, Basel, Switzerland.
License
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 2076-3921
Volume
  • 8
Issue
  • 1
Grant/Funding Information
  • The authors of this review article are supported by the National Cancer Institute and National Institute of Environmental Health Sciences under award numbers R33 ES025645 (C.M.F., R.H., A.W.T.), U01 CA215848 (C.M.F., M.L.K., T.E.F., A.W.T.), R01 GM119227 (L.B.P. and W.T.L.) and F30 CA224968 (J.E.L.).
Abstract
  • Peroxiredoxins have a long-established cellular function as regulators of redox metabolism by catalyzing the reduction of peroxides (e.g., H 2 O 2 , lipid peroxides) with high catalytic efficiency. This activity is also critical to the initiation and relay of both phosphorylation and redox signaling in a broad range of pathophysiological contexts. Under normal physiological conditions, peroxiredoxins protect normal cells from oxidative damage that could promote oncogenesis (e.g., environmental stressors). In cancer, higher expression level of peroxiredoxins has been associated with both tumor growth and resistance to radiation therapies. However, this relationship between the expression of peroxiredoxins and the response to radiation is not evident from an analysis of data in The Cancer Genome Atlas (TCGA) or NCI60 panel of cancer cell lines. The focus of this review is to summarize the current experimental knowledge implicating this class of proteins in cancer, and to provide a perspective on the value of targeting peroxiredoxins in the management of cancer. Potential biases in the analysis of the TCGA data with respect to radiation resistance are also highlighted.
Author Notes
Keywords
Research Categories
  • Chemistry, Biochemistry
  • Health Sciences, Pharmacology
  • Biology, Molecular

Tools

Relations

In Collection:

Items